

02 Mar 2021 | **News**

QUOTED. 2 March 2021. Michael Coyle.

by

Representatives from cardiac monitoring device manufacturers and professional societies are working together to persuade Medicare carrier Novitas to reconsider its payment rates for extended cardiac monitoring. See what Michael Coyle, iRhythm's CEO, said about it here.

“We believe the evidence that we presented was compelling but can provide no assurances as to if and when Novitas will decide to change the proposed rates.” – Michael Coyle, CEO, iRhythm

- Find out more: [Reimbursement For Long-Term Cardiac Monitoring Remains Uncertain, iRhythm Reports](#)

[Click here](#) for a free trial of *Medtech Insight*